Revelation Biosciences, Inc. Announces Initiation of a Phase IIb Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza

Revelation Biosciences, Inc. announced the site initiation for its Phase IIb viral challenge study to evaluate the efficacy of intranasal REVTx-99 for the preventive treatment of H3N2 influenza in healthy humans.